Skip to content
Clinical Trials – home
Sponsor

Genentech Inc.

United States 1 Dna Way, 94080-4918, United States

About the sponsor

Genentech Inc. funds a broad oncology portfolio spanning advanced melanoma, non-small cell lung cancer, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and advanced prostate cancer. Its studies also include HER2-expressing cancers, KRAS G12C-mutated solid tumors, and other locally advanced or metastatic solid tumors.

  • Advanced melanoma and NRAS-mutant melanoma
  • Breast cancer with ER-positive, HER2-negative disease
  • KRAS-mutant solid tumors and metastatic gastrointestinal cancers
  • B-cell malignancies and multiple myeloma

Research activity also extends to relapsed or refractory multiple myeloma, B-cell malignancies, and other hematologic cancers, alongside solid-tumor programs that target difficult-to-treat metastatic disease.

About Specializations

Genentech Inc. runs clinical trials in conditions such as Breast cancer, Breast cancer metastatic, Hormone receptor positive breast cancer, Colitis ulcerative, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Genentech Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Genentech Inc.
Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:RO7837195
  • Sponsor:Genentech Inc.
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Vanglusagene Ensiparvovec
  • Sponsor:Genentech Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vixarelimab
  • Sponsor:Genentech Inc.

Colitis ulcerative

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Genentech Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7288817
  • Sponsor:Genentech Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Genentech Inc.
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.